跳转至内容
Merck
CN
  • A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.

A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.

Japanese journal of clinical oncology (2013-03-20)
Mototsugu Shimokawa, Seiki Hasegawa, Kazuya Fukuoka, Morihito Okada, Kohei Yokoi, Fumihiro Tanaka, Takeharu Yamanaka, Takashi Daimon, Takashi Nakano
摘要

A prospective multi-institutional study has been initiated in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by pleurectomy/decortication aimed at macroscopic complete resection in patients with resectable malignant pleural mesothelioma. The study was initiated on September 2012, for which 24 patients will be recruited over a period of 2 years. The primary endpoint is the macroscopic complete resection rate, regardless of the surgical technique employed (i.e. pleurectomy/decortication or extrapleural pneumonectomy). The secondary endpoints are the pleurectomy/decortication rate, macroscopic complete resection rate by pleurectomy/decortication, pulmonary function at 3 months after surgery, adverse events, treatment-related mortality, response rate to chemotherapy and 3-year overall survival rate.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
鸟嘌呤, 98%
Supelco
鸟嘌呤, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
鸟嘌呤, BioUltra